Search
CLX-0921
go.drugbank.com/drugs/DB05854ExperimentalCLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones.
Methyl-D9-choline
go.drugbank.com/drugs/DB12628InvestigationalMethyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).
Parsaclisib
go.drugbank.com/drugs/DB14867InvestigationalParsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
Narazaciclib
go.drugbank.com/drugs/DB19038InvestigationalNarazaciclib is under investigation in clinical trial NCT06351644 (On 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed And/or Refractory Multiple Myeloma).
Norelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalNorelgestromin was first approved in the United States in 2001 as the progestin in a norelgestromin and ethinyl estradiol transdermal contraceptive system.[L63816] … It is administered transdermally in combination with the estrogen [ethinyl estradiol], delivering both hormones systemically over a 7-day wear period.
rhMBL
go.drugbank.com/drugs/DB05237InvestigationalrhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).
Ciglitazone
go.drugbank.com/drugs/DB09201ExperimentalCiglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome.
Triazavirin
go.drugbank.com/drugs/DB15622Investigational[A191709,A191625,A191916] It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications. … Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain.
Resiquimod
go.drugbank.com/drugs/DB06530InvestigationalA substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells.